AbbVie After Purchase Apogee? Is It a Buy Now for Investors
AbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
Learn the telltale signs you should revise your budget, including income changes, expense spikes, and shifting priorities.
24,979 articlesAbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
In this stock market today update, Intel pulls back as AI bubble risk concerns rise, even as AI-driven momentum suppo...
Lawmakers warn that granting a national bank charter to a crypto-focused issuer could undermine financial integrity a...
As housing activity cools, real estate agents should rethink how they measure success. This report explains why chasi...
A growing platform rolls out an AI tool that lets users convert ideas into investable indices, with an uncapped 1% ma...
A prominent investor takes a sizable stake in BrightSpring Health Services, sparking renewed attention on BTSG stock....
Geopolitics and energy markets collide as Iran-related headlines drive price moves. Investors are reassessing risk, h...
WeRide (WRD) is navigating growth with ride-hailing, delivery, and autonomous tech. This Q1 2026 earnings-focused ana...
Lemonade is betting big on AI to transform how people buy insurance and file claims. This article digs into what lemo...
AI agents are changing how software works for businesses. This piece explains why platforms like ServiceNow and Palan...
As SPIR prepares for 2025, investors want clarity on revenue mix, profitability, and cash flow. This guide breaks dow...
As UNFI approaches its 2026 earnings call, investors want clarity on margins, growth drivers, and capital strategy. T...